The insights of novel coronavirus disease 2019 (COVID-19): Current understanding, research and therapeutic updates

2021 ◽  
Vol 15 ◽  
Author(s):  
Dudala Sai Sushma ◽  
Varun Jaiswal ◽  
Arvind Verma ◽  
Asha Sharma ◽  
Tarun Pal
Keyword(s):  
Vaccine Development ◽  
Current Understanding ◽  
Effective Vaccine ◽  
The Novel ◽  
Biological Drugs ◽  
Plasma Therapy ◽  
Approaches To Study ◽  
Public Repositories ◽  
Novel Coronavirus ◽  
Patented Inventions

Background: Humans can be infected with various coronaviruses that cause serious illness and death. One such pandemic strain of coronavirus was recently identified in December 2019 and lead to a devastating outbreak in Wuhan city of China. It is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is highly contagious which causes symptoms such as fever, cough and shortness of breath. Objective: The objective of this review is to highlight the current understanding, research and therapeutic updates of the novel coronavirus disease 2019 (COVID-19). Methods: A thorough literature search was conducted for research papers and patents in context to COVID-19. All articles with respect to this subject was taken from various public repositories such as Google Scholar, Pubmed, ScienceDirect (Elsevier), Springer, Web of Science, etc. Results: The present analysis showed that key areas of the inventions were the vaccines and diagnostic kits apart from the composition for the treatment of CoV. It was also observed that no specific vaccine treatments are available for the treatment of 2019-nCov; however, developing novel chemical or biological drugs and kits for early diagnosis, prevention, and disease management is the primary governing topic among the patented inventions. The present study also indicates potential research opportunities for the future, particularly to combat 2019-nCoV. The current focus of the researches has turned towards developing four potential treatments including development of candidate vaccine, development of novel potential drugs, repurposing of existing drugs and development of convalescent plasma therapy. The PCR based diagnosis is the gold standard for the COVID-19 testing but it require resource time, expertise and high associated cost hence the researchers are also developing different diagnosis methods for the COVID-19. Although vaccines are being developed by various companies and have passed the pre-clinical stages but still there exists no guarantee for these to become the effective vaccine. The current treatments which are being used for COVID-19 patients are not well established and have limited success. Conclusion: The pandemic has challenged the medical, economic and public health infrastructure across globe. There is urgent need to explore all available and possible methods/approaches to study this disease for drug and vaccine development at the earliest.

scholarly journals COVID-19 vaccine hesitancy is associated with beliefs on the origin of the novel coronavirus in the UK and Turkey

2020 ◽  
pp. 1-3 ◽  
Author(s):  
Gul Deniz Salali ◽  
Mete Sefa Uysal
Keyword(s):  
Online Survey ◽  
Vaccine Development ◽  
Research Effort ◽  
Vaccine Hesitancy ◽  
Effective Vaccine ◽  
The Novel ◽  
Natural Origin ◽  
The Public ◽  
Novel Coronavirus ◽  
The Uk

Abstract Background Much research effort is focused on developing an effective vaccine for combatting coronavirus disease 2019 (COVID-19). Vaccine development itself, however, will not be enough given that a sufficient amount of people will need to be vaccinated for widespread immunity. Vaccine hesitancy is on the rise, varies across countries, and is associated with conspiratorial worldview. Given the rise in COVID-19-related conspiracy theories, we aimed to examine the levels of COVID-19 vaccine hesitancy and its association with beliefs on the origin of the novel coronavirus in a cross-cultural study. Methods We conducted an online survey in the UK (N = 1088) and Turkey (N = 3936), and gathered information on participants' willingness to vaccinate for a potential COVID-19 vaccine, beliefs on the origin of the novel coronavirus, and several behavioural and demographic predictors (such as anxiety, risk perception, government satisfaction levels) that influence vaccination and origin beliefs. Results In all, 31% of the participants in Turkey and 14% in the UK were unsure about getting themselves vaccinated for a COVID-19 vaccine. In both countries, 3% of the participants rejected to be vaccinated. Also, 54% of the participants in Turkey and 63% in the UK believed in the natural origin of the novel coronavirus. Believing in the natural origin significantly increased the odds of COVID-19 vaccine acceptance. Conclusions Our results point at a concerning level of COVID-19 vaccine hesitancy, especially in Turkey, and suggest that wider communication of the scientific consensus on the origin of the novel coronavirus with the public may help future campaigns targeting COVID-19 vaccine hesitancy.

scholarly journals Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions

2020 ◽  
Vol 245 (11) ◽  
pp. 964-969 ◽  
Author(s):  
Manasi P Jogalekar ◽  
Anurag Veerabathini ◽  
Prakash Gangadaran
Keyword(s):  
Clinical Trials ◽  
Vaccine Development ◽  
Genome Structure ◽  
Genetic Material ◽  
Effective Vaccine ◽  
The Novel ◽  
Causative Agents ◽  
Novel Coronavirus ◽  
Spreading Potential ◽  
Conventional Vaccine

Novel 2019 coronavirus has created havoc across the globe since its emergence in December 2019 in Wuhan, China, and fast spreading potential. While we were able to identify the causative agent within a few days of the disease outbreak, several questions still remain unanswered. In this review, we discuss the extent of virus spread, current statistics, SARS-CoV-2 genome organization, comparison between the novel coronavirus and causative agents involved in previous outbreaks, ongoing clinical trials and myths associated with the virus. Lastly, we provide insights into the future perspectives which could prove useful for the scientific community as they work on finding the cure against the disease. Impact statement Early availability of the sequence, the genetic material of SARS-CoV-2 (the virus that causes COVID-19), has prompted efforts towards identifying a safe and effective vaccine in the current public health emergency. To that end, understanding the pathophysiology of disease is crucial for scientists around the world. Since conventional vaccine development and manufacturing may take several years, it is important to think about alternative strategies that we could use to mitigate imminent catastrophe. We hope that this article will open up new avenues and provide insights that could potentially save hundreds of lives affected by COVID-19.

scholarly journals Strategies for Vaccination: Conventional Vaccine Approaches Versus New-Generation Strategies in Combination with Adjuvants

Pharmaceutics ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 140
Author(s):  
Abdellatif Bouazzaoui ◽  
Ahmed A. H. Abdellatif ◽  
Faisal A. Al-Allaf ◽  
Neda M. Bogari ◽  
Saied Al-Dehlawi ◽  
...  
Keyword(s):  
Viral Vectors ◽  
Protein Production ◽  
Vaccine Development ◽  
Effective Vaccine ◽  
The Novel ◽  
Research Teams ◽  
Advantages And Disadvantages ◽  
Rapid Spread ◽  
New Generation ◽  
Conventional Vaccine

The current COVID-19 pandemic, caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), has raised significant economic, social, and psychological concerns. The rapid spread of the virus, coupled with the absence of vaccines and antiviral treatments for SARS-CoV-2, has galvanized a major global endeavor to develop effective vaccines. Within a matter of just a few months of the initial outbreak, research teams worldwide, adopting a range of different strategies, embarked on a quest to develop effective vaccine that could be effectively used to suppress this virulent pathogen. In this review, we describe conventional approaches to vaccine development, including strategies employing proteins, peptides, and attenuated or inactivated pathogens in combination with adjuvants (including genetic adjuvants). We also present details of the novel strategies that were adopted by different research groups to successfully transfer recombinantly expressed antigens while using viral vectors (adenoviral and retroviral) and non-viral delivery systems, and how recently developed methods have been applied in order to produce vaccines that are based on mRNA, self-amplifying RNA (saRNA), and trans-amplifying RNA (taRNA). Moreover, we discuss the methods that are being used to enhance mRNA stability and protein production, the advantages and disadvantages of different methods, and the challenges that are encountered during the development of effective vaccines.

scholarly journals Synthesis and immunological evaluation of synthetic peptide based anti-SARS-CoV-2 vaccine candidates

2021 ◽  
Author(s):  
Qingyu Zhao ◽  
Yanan Gao ◽  
Min Xiao ◽  
Xuefei Huang ◽  
Xuanjun Wu
Keyword(s):  
Synthetic Peptide ◽  
Spike Protein ◽  
Effective Vaccine ◽  
The Novel ◽  
Vaccine Candidates ◽  
Peptide Epitopes ◽  
Novel Coronavirus ◽  
Immunological Evaluation

For prevention of the coronavirus disease 2019 caused by the novel coronavirus SARS-CoV-2, an effective vaccine is critical. Herein, several potential peptide epitopes from the spike protein of SARS-CoV-2 have...

Nanovaccine: A hope to triumph the battle against novel Coronavirus disease 2019 (COVID-19)

2021 ◽  
Vol 15 ◽  
Author(s):  
Anurag Singh ◽  
Anand Maurya ◽  
Gaurav Mishra ◽  
Rajendra Awasthi ◽  
Kamal Dua ◽  
...  
Keyword(s):  
Subunit Vaccine ◽  
Goblet Cells ◽  
Spike Protein ◽  
Effective Vaccine ◽  
The Novel ◽  
Infection Site ◽  
Peptide Vaccines ◽  
Ciliated Cells ◽  
Novel Coronavirus ◽  
Major Target

Background: The novel coronavirus 2019 (COVID-19) infection has caused the global emergence of coronavirus in humans during the last 12 months. Till May 11, 2021, the confirmed global COVID-19 cases and deaths reached 158551526 and 3296855, respectively. Methods: Goblet cells and ciliated cells in the nose act as the initial infection site of SARS-CoV-2. Thus, mucus immunity is important to protect from infection. The outburst of SARS-CoV-2 infection can be halted only when an effective vaccine will be developed. Results: Globally, over 100 different vaccines are under investigation, including DNA vaccines, RNA vaccines, inactivated virus vaccines, adenovirus-based vaccines, recombinant/ subunit protein vaccines, peptide vaccines, and virus-like particles etc. Inactivated virus vaccines and mRNA, and adenovirus-based vaccines have moved fast into clinical trials. Conclusion: : Vaccines containing spike protein of SARS-CoV as subunit could effectively prevent binding of coronavirus to the host cell and membrane fusion. Thus, spike protein can be used as a major target for subunit vaccine preparation.

scholarly journals SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far

Pathogens ◽  
2020 ◽  
Vol 9 (3) ◽  
pp. 231 ◽  
Author(s):  
Firas A. Rabi ◽  
Mazhar S. Al Zoubi ◽  
Ghena A. Kasasbeh ◽  
Dunia M. Salameh ◽  
Amjad D. Al-Nasser
Keyword(s):  
Vaccine Development ◽  
Current Knowledge ◽  
Treatment Options ◽  
The Novel ◽  
Clinical Criteria ◽  
Health Authorities ◽  
Close Relationship ◽  
Public Health Authorities ◽  
Molecular Information ◽  
Novel Coronavirus

In December 2019, a cluster of fatal pneumonia cases presented in Wuhan, China. They were caused by a previously unknown coronavirus. All patients had been associated with the Wuhan Wholefood market, where seafood and live animals are sold. The virus spread rapidly and public health authorities in China initiated a containment effort. However, by that time, travelers had carried the virus to many countries, sparking memories of the previous coronavirus epidemics, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and causing widespread media attention and panic. Based on clinical criteria and available serological and molecular information, the new disease was called coronavirus disease of 2019 (COVID-19), and the novel coronavirus was called SARS Coronavirus-2 (SARS-CoV-2), emphasizing its close relationship to the 2002 SARS virus (SARS-CoV). The scientific community raced to uncover the origin of the virus, understand the pathogenesis of the disease, develop treatment options, define the risk factors, and work on vaccine development. Here we present a summary of current knowledge regarding the novel coronavirus and the disease it causes.

scholarly journals Microbes, Clinical trials, Drug Discovery, and Vaccine Development: The Current Perspectives

2021 ◽  
Vol 4 (4) ◽  
pp. 311-323
Author(s):  
Venkataramana Kandi ◽  
Tarun Kumar Suvvari ◽  
Sabitha Vadakedath ◽  
Vikram Godishala
Keyword(s):  
Drug Discovery ◽  
Genetic Variants ◽  
Vaccine Development ◽  
Treatment Options ◽  
Morbidity And Mortality ◽  
Therapeutic Interventions ◽  
Multi Drug Resistance ◽  
The Novel ◽  
Normal Human ◽  
Novel Coronavirus

Because of the frequent emergence of novel microbial species and the re-emergence of genetic variants of hitherto known microbes, the global healthcare system, and human health has been thrown into jeopardy. Also, certain microbes that possess the ability to develop multi-drug resistance (MDR) have limited the treatment options in cases of serious infections, and increased hospital and treatment costs, and associated morbidity and mortality. The recent discovery of the novel Coronavirus (n-CoV), the Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) that is causing the CoV Disease-19 (COVID-19) has resulted in severe morbidity and mortality throughout the world affecting normal human lives. The major concern with the current pandemic is the non-availability of specific drugs and an incomplete understanding of the pathobiology of the virus. It is therefore important for pharmaceutical establishments to envisage the discovery of therapeutic interventions and potential vaccines against the novel and MDR microbes. Therefore, this review is attempted to update and explore the current perspectives in microbes, clinical research, drug discovery, and vaccine development to effectively combat the emerging novel and re-emerging genetic variants of microbes.

scholarly journals Rapid Serological Testing for Managing the COVID-19 Pandemic: A Review

2021 ◽  
Vol 11 (1) ◽  
pp. 99-107
Author(s):  
Sultan M. Faheem ◽  
Jancie D’Mello ◽  
Sultan M. Kaleem ◽  
Burra V. L. S. Prasad ◽  
Khalid Siddiqui
Keyword(s):  
Protective Immunity ◽  
Effective Vaccine ◽  
The Novel ◽  
Serological Testing ◽  
Prophylactic Measure ◽  
Public Health Policies ◽  
Effective Care ◽  
Novel Coronavirus ◽  
And Control

With the onset of the novel coronavirus disease pandemic (COVID-19) that emerged from Wuhan in China, the need of the hour can be summarized into two groups. The first one is a potent vaccine as a prophylactic measure to prevent the virus from infecting people, and the second is a rapid diagnosis of the disease to help healthcare professionals and government authorities to plan and control the spread and provide effective care and treatment. This review delves into the latter, describing the COVID-19 and its treatment, including the race for an effective vaccine, and highlighting the role of serological testing in managing the pandemic since a well-designed study to understand mechanisms and serological correlations of protective immunity is crucial for rational clinical and public health policies. In conclusion, swift vaccination and response tactics, such as social distancing, hand hygiene, wearing of masks, and, if required, lockdown practices continue to be important in managing the pandemic while carefully monitoring any possible outbreak due to the variants.

scholarly journals Pharmacotherapy for COVID-19: A Ray of Hope

2021 ◽  
Author(s):  
Mayank Kapoor ◽  
Prasan Kumar Panda ◽  
Vivek Mohanty
Keyword(s):  
Large Scale ◽  
Kinase Inhibitors ◽  
Viral Infections ◽  
Treatment Options ◽  
Interferon Alfa ◽  
The Novel ◽  
Plasma Therapy ◽  
Therapeutic Drugs ◽  
Novel Coronavirus ◽  
Multiple Drugs

Most viral infections have limited treatment options available and the same holds for COVID-19, its causative agent being the SARS-CoV-2 virus. Drugs used in the past against Severe Acute Respiratory Syndrome (SARS) or Middle East Respiratory Syndrome (MERS) viruses, which belong to the same family of viruses as the novel Coronavirus included ribavirin, interferon (alfa and beta), lopinavir-ritonavir combination, and corticosteroids. There remains controversy regarding their efficacy to date, except for the last one. Hence, large-scale multicentric trials are being conducted involving multiple drugs. Chloroquine and hydroxy-chloroquine were initially taking the race ahead but have now been rejected. Remdesivir was a promising candidate, for which the FDA had issued an emergency use authorization, but now is not recommended by the WHO. Convalescent plasma therapy had promising results in the early severe viremia phase, but the PLACID trial made an obscure end. Only corticosteroids have shown demonstrable benefits in improving mortality rates among severe COVID-19 cases. Many new modalities like monoclonal antibodies and tyrosine kinase inhibitors are discussed. In this chapter, we review the therapeutic drugs under investigation for the COVID-19 treatment, their mode of action, degree of effectiveness, and recommendations by different centers regarding their use in current settings.

scholarly journals Severity of Coronavirus Disease 2019 in Patients with Cancer

2020 ◽  
Vol 4 (2) ◽  
pp. 119-126
Author(s):  
Zahraa Qusairy ◽  
Miran Rada
Keyword(s):  
Global Health ◽  
Treatment Options ◽  
Underlying Disease ◽  
Therapeutic Agents ◽  
The Novel ◽  
Supportive Treatment ◽  
Plasma Therapy ◽  
Patients With Cancer ◽  
Novel Coronavirus

The outbreak of the novel coronavirus disease 2019 (COVID-19) has appeared to be one of the biggest global health threats worldwide with no specific therapeutic agents. As of August 2020, over 22.4 million confirmed cases and more than 788,000 deaths have been reported globally, and the toll is expected to increase before the pandemic is over. Given the aggressive nature of their underlying disease, cancer patients seem to be more vulnerable to COVID-19 and various studies have confirmed this hypothesis. Herein, we review the current information regarding the role of cancer in SARS-CoV-2 infections. Moreover, we discuss the effective supportive treatment options for COVID-19 including Dexamethasone, Tocilizumab and Remdesivir and convalescent plasma therapy (CPT), as well as discuss their efficacy in COVID-19 patients with cancer.

Sign in / Sign up

Export Citation Format

Share Document